Eli Lilly is plunging into vaccine research through the acquisition of three biotech companies—Curevo, LimmaTech, and Vaccine Co.—in deals valued at close to $4 billion combined. The move signals a strategic pivot for the Indianapolis-based drugmaker, which has long focused on diabetes, oncology, and immunology, into the infectious disease space.
Curevo specializes in shingles vaccines, while LimmaTech develops vaccines targeting bacterial infections such as typhoid and cholera. Vaccine Co., whose identity has not been formally disclosed beyond its utility moniker, rounds out the trio with early-stage programs against respiratory pathogens. None of the companies have approved products, making this a bet on preclinical and clinical-stage candidates.
The acquisitions are expected to close in the coming months, subject to regulatory clearances. Lilly has not disclosed specific timelines for advancing the acquired assets toward human trials or approval filings. The company’s recent foray into vaccines comes as it seeks to diversify revenue streams beyond its blockbuster drugs Mounjaro and Zepbound.
Investors reacted cautiously, with Lilly shares trading flat on the news. The $4 billion price tag, while modest for Lilly, represents a significant commitment to an unproven pipeline in a field dominated by players like Moderna, Pfizer, and GSK. The competitive landscape for shingles vaccines alone includes GSK’s Shingrix, which generated over $4 billion in sales last year.
Analysts note that success is far from assured. Vaccine development carries high failure rates, and Lilly lacks deep experience in large-scale vaccine manufacturing. The company will need to integrate disparate teams and technologies rapidly to avoid delays, a challenge that has tripped up other pharma giants in similar expansion efforts.